People

Celebrities and Royals from around the world. Right on schedule.

News

Daily news and events, covered by our international photographers.

Features

Odd, funny and touchy images. Be amazed.

Styling

Fashion and design trends.

Portrait

Premium Portraiture.

Reportage

In-depth Coverage.

Creative

Selected stock imagery.

Dukas Bildagentur
request@dukas.ch
+41 44 298 50 00

Your search:

76 result(s) in 0.01 s

  • FDA approves deep-brain stimulation treatment for Parkinsons patients
    DUKAS_183263421_POL
    FDA approves deep-brain stimulation treatment for Parkinsons patients
    3/21/2025 - Palo Alto, California, USA: Parkinson’s patient Keith Krehbiel wears a Medtronic device during his treatment with neurologist Dr. Helen Bronte-Stewart at the Stanford Neuroscience Health Center in Palo Alto, Calif. on Friday, March 21, 2025. The FDA has recently approved a personalized treatment for Parkinson's, adaptive deep-brain stimulation. For the first time in the U.S., Stanford experts are using it for patients. Krehbiel, 70, a recently retired political science and ethics professor at Stanford University, was diagnosed with Parkinson’s in 1997. (Yalonda M. James / San Francisco Chronicle / Polaris) (FOTO:DUKAS/POLARIS)
    ©San Francisco Chronicle/Yalonda M. James

     

  • FDA approves deep-brain stimulation treatment for Parkinsons patients
    DUKAS_183263420_POL
    FDA approves deep-brain stimulation treatment for Parkinsons patients
    3/24/2025 - San Francisco, California, USA: Pat Wright, left, watches her partner Parkinson’s patient Deb Zeyen, former VP in Marketing and Internet Development for CBS Television Network, as she demonstrates her motor skills during her treatment with neurologist Simon Little, UCSF, at the UCSF Weill Institute in San Francisco on Monday, March 24, 2025. The FDA has recently approved a personalized treatment for Parkinson's, adaptive deep-brain stimulation. (Yalonda M. James / San Francisco Chronicle / Polaris) (FOTO:DUKAS/POLARIS)
    ©San Francisco Chronicle/Yalonda M. James

     

  • FDA approves deep-brain stimulation treatment for Parkinsons patients
    DUKAS_183263419_POL
    FDA approves deep-brain stimulation treatment for Parkinsons patients
    3/24/2025 - San Francisco, California, USA: Parkinson’s patient Deb Zeyen, former VP in Marketing and Internet Development for CBS Television Network, walks in a hallway to demonstrate her motor skills during her treatment with neurologist Simon Little, UCSF, right, at the UCSF Weill Institute in San Francisco on Monday, March 24, 2025. The FDA has recently approved a personalized treatment for Parkinson's, adaptive deep-brain stimulation. (Yalonda M. James / San Francisco Chronicle / Polaris) (FOTO:DUKAS/POLARIS)
    ©San Francisco Chronicle/Yalonda M. James

     

  • FDA approves deep-brain stimulation treatment for Parkinsons patients
    DUKAS_183263418_POL
    FDA approves deep-brain stimulation treatment for Parkinsons patients
    3/24/2025 - San Francisco, California, USA: Nurse practitioner Monica Volz, with UCSF’s deep-brain stimulation program, works with neurologist Simon Little, UCSF, during a treatment with Parkinson’s patient Deb Zeyen, both not pictured, former VP in Marketing and Internet Development for CBS Television Network, at the UCSF Weill Institute in San Francisco on Monday, March 24, 2025. The FDA has recently approved a personalized treatment for Parkinson's, adaptive deep-brain stimulation. (Yalonda M. James / San Francisco Chronicle / Polaris) (FOTO:DUKAS/POLARIS)
    ©San Francisco Chronicle/Yalonda M. James

     

  • FDA approves deep-brain stimulation treatment for Parkinsons patients
    DUKAS_183263417_POL
    FDA approves deep-brain stimulation treatment for Parkinsons patients
    3/24/2025 - San Francisco, California, USA: Parkinson’s patient Deb Zeyen, former VP in Marketing and Internet Development for CBS Television Network, attends her treatment with neurologist Simon Little, UCSF, at the UCSF Weill Institute in San Francisco on Monday, March 24, 2025. The FDA has recently approved a personalized treatment for Parkinson's, adaptive deep-brain stimulation. (Yalonda M. James / San Francisco Chronicle / Polaris) (FOTO:DUKAS/POLARIS)
    ©San Francisco Chronicle/Yalonda M. James

     

  • FDA approves deep-brain stimulation treatment for Parkinsons patients
    DUKAS_183263416_POL
    FDA approves deep-brain stimulation treatment for Parkinsons patients
    3/21/2025 - Palo Alto, California, USA: Parkinson’s patient John L. Lipp, CEO, Friends of the Alameda Animal Shelter (FAAS) wears a Medtronic device during treatment with neurologist Gaurav Chattree, Stanford University, not pictured, at the Stanford Neuroscience Health Center in Palo Alto, Calif. on Friday, March 21, 2025. The FDA has recently approved a personalized treatment for Parkinson's, adaptive deep-brain stimulation. For the first time in the U.S., Stanford experts are using it for patients. (Yalonda M. James / San Francisco Chronicle / Polaris) (FOTO:DUKAS/POLARIS)
    ©San Francisco Chronicle/Yalonda M. James

     

  • FDA approves deep-brain stimulation treatment for Parkinsons patients
    DUKAS_183263414_POL
    FDA approves deep-brain stimulation treatment for Parkinsons patients
    3/21/2025 - Palo Alto, California, USA: Neurologist Dr. Helen Bronte-Stewart works with Parkinson’s patient Keith Krehbiel during a treatment at the Stanford Neuroscience Health Center in Palo Alto, Calif. on Friday, March 21, 2025. The FDA has recently approved a personalized treatment for Parkinson's, adaptive deep-brain stimulation. For the first time in the U.S., Stanford experts are using it for patients. Krehbiel, 70, a recently retired political science and ethics professor at Stanford University, was diagnosed with Parkinson’s in 1997. (Yalonda M. James / San Francisco Chronicle / Polaris) (FOTO:DUKAS/POLARIS)
    ©San Francisco Chronicle/Yalonda M. James

     

  • FDA approves deep-brain stimulation treatment for Parkinsons patients
    DUKAS_183263412_POL
    FDA approves deep-brain stimulation treatment for Parkinsons patients
    3/21/2025 - Palo Alto, California, USA: Parkinson’s patient John L. Lipp, CEO, Friends of the Alameda Animal Shelter (FAAS), walks in a hallway during his treatment with neurologist Gaurav Chattree, Stanford University (not pictured), and other medical professionals at the Stanford Neuroscience Health Center in Palo Alto, Calif. on Friday, March 21, 2025. The FDA has recently approved a personalized treatment for Parkinson's, adaptive deep-brain stimulation. For the first time in the U.S., Stanford experts are using it for patients. (Yalonda M. James / San Francisco Chronicle / Polaris) (FOTO:DUKAS/POLARIS)
    ©San Francisco Chronicle/Yalonda M. James

     

  • FDA approves deep-brain stimulation treatment for Parkinsons patients
    DUKAS_183263410_POL
    FDA approves deep-brain stimulation treatment for Parkinsons patients
    3/21/2025 - Palo Alto, California, USA: Neurologist Dr. Helen Bronte-Stewart works with Parkinson’s patient Keith Krehbiel during a treatment at the Stanford Neuroscience Health Center in Palo Alto, Calif. on Friday, March 21, 2025. The FDA has recently approved a personalized treatment for Parkinson's, adaptive deep-brain stimulation. For the first time in the U.S., Stanford experts are using it for patients. Krehbiel, 70, a recently retired political science and ethics professor at Stanford University, was diagnosed with Parkinson’s in 1997. (Yalonda M. James / San Francisco Chronicle / Polaris) (FOTO:DUKAS/POLARIS)
    ©San Francisco Chronicle/Yalonda M. James

     

  • FDA approves deep-brain stimulation treatment for Parkinsons patients
    DUKAS_183263406_POL
    FDA approves deep-brain stimulation treatment for Parkinsons patients
    3/21/2025 - Palo Alto, California, USA: Neurologist Dr. Helen Bronte-Stewart, left, and Pearl Yamaguchi, senior field clinical research manager for Medtronic, read a monitor while treating Parkinson’s patient Keith Krehbiel (not pictured) at the Stanford Neuroscience Health Center in Palo Alto, Calif. on Friday, March 21, 2025. The FDA has recently approved a personalized treatment for Parkinson's, adaptive deep-brain stimulation. For the first time in the U.S., Stanford experts are using it for patients. Krehbiel, 70, a recently retired political science and ethics professor at Stanford University, was diagnosed with Parkinson’s in 1997. (Yalonda M. James / San Francisco Chronicle / Polaris) (FOTO:DUKAS/POLARIS)
    ©San Francisco Chronicle/Yalonda M. James

     

  • FDA approves deep-brain stimulation treatment for Parkinsons patients
    DUKAS_183263403_POL
    FDA approves deep-brain stimulation treatment for Parkinsons patients
    3/21/2025 - Palo Alto, California, USA: Neurologist Dr. Helen Bronte-Stewart (not pictured) works with Parkinson’s patient Keith Krehbiel during a treatment at the Stanford Neuroscience Health Center in Palo Alto, Calif. on Friday, March 21, 2025. The FDA has recently approved a personalized treatment for Parkinson's, adaptive deep-brain stimulation. For the first time in the U.S., Stanford experts are using it for patients. Krehbiel, 70, a recently retired political science and ethics professor at Stanford University, was diagnosed with Parkinson’s in 1997. (Yalonda M. James / San Francisco Chronicle / Polaris) (FOTO:DUKAS/POLARIS)
    ©San Francisco Chronicle/Yalonda M. James

     

  • FDA approves deep-brain stimulation treatment for Parkinsons patients
    DUKAS_183263402_POL
    FDA approves deep-brain stimulation treatment for Parkinsons patients
    3/21/2025 - Palo Alto, California, USA: Neurologist Dr. Helen Bronte-Stewart reads a monitor while treating Parkinson’s patient Keith Krehbiel (not pictured) at the Stanford Neuroscience Health Center in Palo Alto, Calif. on Friday, March 21, 2025. The FDA has recently approved a personalized treatment for Parkinson's, adaptive deep-brain stimulation. For the first time in the U.S., Stanford experts are using it for patients. Krehbiel, 70, a recently retired political science and ethics professor at Stanford University, was diagnosed with Parkinson’s in 1997. (Yalonda M. James / San Francisco Chronicle / Polaris) (FOTO:DUKAS/POLARIS)
    ©San Francisco Chronicle/Yalonda M. James

     

  • FDA approves deep-brain stimulation treatment for Parkinsons patients
    DUKAS_183263401_POL
    FDA approves deep-brain stimulation treatment for Parkinsons patients
    3/21/2025 - Palo Alto, California, USA: Neurologist Dr. Helen Bronte-Stewart works with Parkinson’s patient Keith Krehbiel during a treatment at the Stanford Neuroscience Health Center in Palo Alto, Calif. on Friday, March 21, 2025. The FDA has recently approved a personalized treatment for Parkinson's, adaptive deep-brain stimulation. For the first time in the U.S., Stanford experts are using it for patients. Krehbiel, 70, a recently retired political science and ethics professor at Stanford University, was diagnosed with Parkinson’s in 1997. (Yalonda M. James / San Francisco Chronicle / Polaris) (FOTO:DUKAS/POLARIS)
    ©San Francisco Chronicle/Yalonda M. James

     

  • FDA approves deep-brain stimulation treatment for Parkinsons patients
    DUKAS_183263400_POL
    FDA approves deep-brain stimulation treatment for Parkinsons patients
    3/24/2025 - San Francisco, California, USA: Parkinson’s patient Deb Zeyen, former VP in Marketing and Internet Development for CBS Television Network, walks in a hallway to demonstrate her motor skills during her treatment with neurologist Simon Little, UCSF, right, at the UCSF Weill Institute in San Francisco on Monday, March 24, 2025. The FDA has recently approved a personalized treatment for Parkinson's, adaptive deep-brain stimulation. (Yalonda M. James / San Francisco Chronicle / Polaris) (FOTO:DUKAS/POLARIS)
    ©San Francisco Chronicle/Yalonda M. James

     

  • FDA approves deep-brain stimulation treatment for Parkinsons patients
    DUKAS_183263399_POL
    FDA approves deep-brain stimulation treatment for Parkinsons patients
    3/24/2025 - San Francisco, California, USA: Parkinson’s patient Deb Zeyen, former VP in Marketing and Internet Development for CBS Television Network, demonstrates her motor skills during her treatment with neurologist Simon Little, UCSF, at the UCSF Weill Institute in San Francisco on Monday, March 24, 2025. The FDA has recently approved a personalized treatment for Parkinson's, adaptive deep-brain stimulation. (Yalonda M. James / San Francisco Chronicle / Polaris) (FOTO:DUKAS/POLARIS)
    ©San Francisco Chronicle/Yalonda M. James

     

  • FDA approves deep-brain stimulation treatment for Parkinsons patients
    DUKAS_183263398_POL
    FDA approves deep-brain stimulation treatment for Parkinsons patients
    3/24/2025 - San Francisco, California, USA: Parkinson’s patient Deb Zeyen, former VP in Marketing and Internet Development for CBS Television Network, walks in a hallway to demonstrate her motor skills during her treatment with neurologist Simon Little, UCSF, right, at the UCSF Weill Institute in San Francisco on Monday, March 24, 2025. The FDA has recently approved a personalized treatment for Parkinson's, adaptive deep-brain stimulation. (Yalonda M. James / San Francisco Chronicle / Polaris) (FOTO:DUKAS/POLARIS)
    ©San Francisco Chronicle/Yalonda M. James

     

  • FDA approves deep-brain stimulation treatment for Parkinsons patients
    DUKAS_183263396_POL
    FDA approves deep-brain stimulation treatment for Parkinsons patients
    3/21/2025 - Palo Alto, California, USA: Neurologist Dr. Helen Bronte-Stewart (not pictured) works with Parkinson’s patient Keith Krehbiel during a treatment at the Stanford Neuroscience Health Center in Palo Alto, Calif. on Friday, March 21, 2025. The FDA has recently approved a personalized treatment for Parkinson's, adaptive deep-brain stimulation. For the first time in the U.S., Stanford experts are using it for patients. Krehbiel, 70, a recently retired political science and ethics professor at Stanford University, was diagnosed with Parkinson’s in 1997. (Yalonda M. James / San Francisco Chronicle / Polaris) (FOTO:DUKAS/POLARIS)
    ©San Francisco Chronicle/Yalonda M. James

     

  • FDA approves deep-brain stimulation treatment for Parkinsons patients
    DUKAS_183263394_POL
    FDA approves deep-brain stimulation treatment for Parkinsons patients
    3/24/2025 - San Francisco, California, USA: Parkinson’s patient Deb Zeyen, former VP in Marketing and Internet Development for CBS Television Network, works on her motor skills during her treatment with neurologist Simon Little, UCSF, at the UCSF Weill Institute in San Francisco on Monday, March 24, 2025. The FDA has recently approved a personalized treatment for Parkinson's, adaptive deep-brain stimulation. (Yalonda M. James / San Francisco Chronicle / Polaris) (FOTO:DUKAS/POLARIS)
    ©San Francisco Chronicle/Yalonda M. James

     

  • FDA approves deep-brain stimulation treatment for Parkinsons patients
    DUKAS_183263392_POL
    FDA approves deep-brain stimulation treatment for Parkinsons patients
    3/24/2025 - San Francisco, California, USA: Parkinson’s patient Deb Zeyen, left, former VP in Marketing and Internet Development for CBS Television Network, attends her treatment with neurologist Simon Little, UCSF, and nurse practitioner Monica Volz, with UCSF’s deep-brain stimulation program, at the UCSF Weill Institute in San Francisco on Monday, March 24, 2025. The FDA has recently approved a personalized treatment for Parkinson's, adaptive deep-brain stimulation. (Yalonda M. James / San Francisco Chronicle / Polaris) (FOTO:DUKAS/POLARIS)
    ©San Francisco Chronicle/Yalonda M. James

     

  • FDA approves deep-brain stimulation treatment for Parkinsons patients
    DUKAS_183263390_POL
    FDA approves deep-brain stimulation treatment for Parkinsons patients
    3/24/2025 - San Francisco, California, USA: Parkinson’s patient Deb Zeyen, former VP in Marketing and Internet Development for CBS Television Network, attends her treatment with neurologist Simon Little, UCSF, at the UCSF Weill Institute in San Francisco on Monday, March 24, 2025. The FDA has recently approved a personalized treatment for Parkinson's, adaptive deep-brain stimulation. (Yalonda M. James / San Francisco Chronicle / Polaris) (FOTO:DUKAS/POLARIS)
    ©San Francisco Chronicle/Yalonda M. James

     

  • FDA approves deep-brain stimulation treatment for Parkinsons patients
    DUKAS_183263388_POL
    FDA approves deep-brain stimulation treatment for Parkinsons patients
    3/21/2025 - Palo Alto, California, USA: Neurologist Gaurav Chattree, second from right, Stanford University, converses with Parkinson’s patient John L. Lipp, CEO, Friends of the Alameda Animal Shelter (FAAS), second from left, during treatment at the Stanford Neuroscience Health Center in Palo Alto, Calif. on Friday, March 21, 2025. The FDA has recently approved a personalized treatment for Parkinson's, adaptive deep-brain stimulation. For the first time in the U.S., Stanford experts are using it for patients. (Yalonda M. James / San Francisco Chronicle / Polaris) (FOTO:DUKAS/POLARIS)
    ©San Francisco Chronicle/Yalonda M. James

     

  • FDA approves deep-brain stimulation treatment for Parkinsons patients
    DUKAS_183263386_POL
    FDA approves deep-brain stimulation treatment for Parkinsons patients
    3/21/2025 - Palo Alto, California, USA: Neurologist Gaurav Chattree, Stanford University, monitors treatment with Parkinson’s patient John L. Lipp, CEO, Friends of the Alameda Animal Shelter (FAAS), not pictured, at the Stanford Neuroscience Health Center in Palo Alto, Calif. on Friday, March 21, 2025. The FDA has recently approved a personalized treatment for Parkinson's, adaptive deep-brain stimulation. For the first time in the U.S., Stanford experts are using it for patients. (Yalonda M. James / San Francisco Chronicle / Polaris) (FOTO:DUKAS/POLARIS)
    ©San Francisco Chronicle/Yalonda M. James

     

  • FDA approves deep-brain stimulation treatment for Parkinsons patients
    DUKAS_183263384_POL
    FDA approves deep-brain stimulation treatment for Parkinsons patients
    3/21/2025 - Palo Alto, California, USA: Neurologist Gaurav Chattree, Stanford University, monitors treatment with Parkinson’s patient John L. Lipp, CEO, Friends of the Alameda Animal Shelter (FAAS), not pictured, at the Stanford Neuroscience Health Center in Palo Alto, Calif. on Friday, March 21, 2025. The FDA has recently approved a personalized treatment for Parkinson's, adaptive deep-brain stimulation. For the first time in the U.S., Stanford experts are using it for patients. (Yalonda M. James / San Francisco Chronicle / Polaris) (FOTO:DUKAS/POLARIS)
    ©San Francisco Chronicle/Yalonda M. James

     

  • FDA approves deep-brain stimulation treatment for Parkinsons patients
    DUKAS_183263382_POL
    FDA approves deep-brain stimulation treatment for Parkinsons patients
    3/21/2025 - Palo Alto, California, USA: Parkinson’s patient John L. Lipp, CEO, Friends of the Alameda Animal Shelter (FAAS), walks in a hallway during his treatment with neurologist Gaurav Chattree, Stanford University (not pictured), and other medical professionals at the Stanford Neuroscience Health Center in Palo Alto, Calif. on Friday, March 21, 2025. The FDA has recently approved a personalized treatment for Parkinson's, adaptive deep-brain stimulation. For the first time in the U.S., Stanford experts are using it for patients. (Yalonda M. James / San Francisco Chronicle / Polaris) (FOTO:DUKAS/POLARIS)
    ©San Francisco Chronicle/Yalonda M. James

     

  • FDA approves deep-brain stimulation treatment for Parkinsons patients
    DUKAS_183263380_POL
    FDA approves deep-brain stimulation treatment for Parkinsons patients
    3/21/2025 - Palo Alto, California, USA: (Left to right): Ken Washington, chief technology officer for Medtronic, and Rob Raike, director of research and technology for Medtronic Neuromodulation, watch live results of Parkinson’s patient John L. Lipp’s treatment with neurologist Gaurav Chattree, Stanford University (both not pictured), at the Stanford Neuroscience Health Center in Palo Alto, Calif. on Friday, March 21, 2025. The FDA has recently approved a personalized treatment for Parkinson's, adaptive deep-brain stimulation. For the first time in the U.S., Stanford experts are using it for patients. (Yalonda M. James / San Francisco Chronicle / Polaris) (FOTO:DUKAS/POLARIS)
    ©San Francisco Chronicle/Yalonda M. James

     

  • FDA approves deep-brain stimulation treatment for Parkinsons patients
    DUKAS_183263378_POL
    FDA approves deep-brain stimulation treatment for Parkinsons patients
    3/21/2025 - Palo Alto, California, USA: Parkinson’s patient John L. Lipp, CEO, Friends of the Alameda Animal Shelter (FAAS), left, displays his motor skills to neurologist Gaurav Chattree, Stanford University (center), and engineer Shrav Ravi, emerging technology field technical consultant with Medtronic, during treatment at the Stanford Neuroscience Health Center in Palo Alto, Calif. on Friday, March 21, 2025. The FDA has recently approved a personalized treatment for Parkinson's, adaptive deep-brain stimulation. For the first time in the U.S., Stanford experts are using it for patients. (Yalonda M. James / San Francisco Chronicle / Polaris) (FOTO:DUKAS/POLARIS)
    ©San Francisco Chronicle/Yalonda M. James

     

  • FDA approves deep-brain stimulation treatment for Parkinsons patients
    DUKAS_183263376_POL
    FDA approves deep-brain stimulation treatment for Parkinsons patients
    3/21/2025 - Palo Alto, California, USA: Parkinson’s patient John L. Lipp, CEO, Friends of the Alameda Animal Shelter (FAAS), attends his treatment with neurologist Gaurav Chattree, Stanford University (not pictured), (not pictured) at the Stanford Neuroscience Health Center in Palo Alto, Calif. on Friday, March 21, 2025. The FDA has recently approved a personalized treatment for Parkinson's, adaptive deep-brain stimulation. For the first time in the U.S., Stanford experts are using it for patients. (Yalonda M. James / San Francisco Chronicle / Polaris) (FOTO:DUKAS/POLARIS)
    ©San Francisco Chronicle/Yalonda M. James

     

  • FDA approves deep-brain stimulation treatment for Parkinsons patients
    DUKAS_183263373_POL
    FDA approves deep-brain stimulation treatment for Parkinsons patients
    3/21/2025 - Palo Alto, California, USA: (Left to right): Donna Gow, senior deep-brain stimulation (DBS) therapy specialist, San Francisco Bay Area, Medtronic, works with Parkinson’s patient Keith Krehbiel, during a treatment at the Stanford Neuroscience Health Center in Palo Alto, Calif. on Friday, March 21, 2025. The FDA has recently approved a personalized treatment for Parkinson's, adaptive deep-brain stimulation. For the first time in the U.S., Stanford experts are using it for patients. Krehbiel, 70, a recently retired political science and ethics professor at Stanford University, was diagnosed with Parkinson’s in 1997. (Yalonda M. James / San Francisco Chronicle / Polaris) (FOTO:DUKAS/POLARIS)
    ©San Francisco Chronicle/Yalonda M. James

     

  • FDA approves deep-brain stimulation treatment for Parkinsons patients
    DUKAS_183263370_POL
    FDA approves deep-brain stimulation treatment for Parkinsons patients
    3/21/2025 - Palo Alto, California, USA: (Left to right): Neurologist Dr. Helen Bronte-Stewart works with Parkinson’s patient Keith Krehbiel as Pearl Yamaguchi, senior field clinical research manager for Medtronic, observes during a treatment at the Stanford Neuroscience Health Center in Palo Alto, Calif. on Friday, March 21, 2025. The FDA has recently approved a personalized treatment for Parkinson's, adaptive deep-brain stimulation. For the first time in the U.S., Stanford experts are using it for patients. (Yalonda M. James / San Francisco Chronicle / Polaris) (FOTO:DUKAS/POLARIS)
    ©San Francisco Chronicle/Yalonda M. James

     

  • FDA approves deep-brain stimulation treatment for Parkinsons patients
    DUKAS_183263369_POL
    FDA approves deep-brain stimulation treatment for Parkinsons patients
    3/21/2025 - Palo Alto, California, USA: Neurologist Dr. Helen Bronte-Stewart works with Parkinson’s patient Keith Krehbiel during a treatment at the Stanford Neuroscience Health Center in Palo Alto, Calif. on Friday, March 21, 2025. The FDA has recently approved a personalized treatment for Parkinson's, adaptive deep-brain stimulation. For the first time in the U.S., Stanford experts are using it for patients. Krehbiel, 70, a recently retired political science and ethics professor at Stanford University, was diagnosed with Parkinson’s in 1997. (Yalonda M. James / San Francisco Chronicle / Polaris) (FOTO:DUKAS/POLARIS)
    ©San Francisco Chronicle/Yalonda M. James

     

  • FDA approves deep-brain stimulation treatment for Parkinsons patients
    DUKAS_183263368_POL
    FDA approves deep-brain stimulation treatment for Parkinsons patients
    3/24/2025 - San Francisco, California, USA: Parkinson’s patient Deb Zeyen, left, former VP in Marketing and Internet Development for CBS Television Network, drinks water during her treatment with neurologist Simon Little, UCSF, at the UCSF Weill Institute in San Francisco on Monday, March 24, 2025. The FDA has recently approved a personalized treatment for Parkinson's, adaptive deep-brain stimulation. (Yalonda M. James / San Francisco Chronicle / Polaris) (FOTO:DUKAS/POLARIS)
    ©San Francisco Chronicle/Yalonda M. James

     

  • FDA approves deep-brain stimulation treatment for Parkinsons patients
    DUKAS_183263367_POL
    FDA approves deep-brain stimulation treatment for Parkinsons patients
    3/24/2025 - San Francisco, California, USA: Parkinson’s patient Deb Zeyen, former VP in Marketing and Internet Development for CBS Television Network, attends her treatment with neurologist Simon Little, UCSF, at the UCSF Weill Institute in San Francisco on Monday, March 24, 2025. The FDA has recently approved a personalized treatment for Parkinson's, adaptive deep-brain stimulation. (Yalonda M. James / San Francisco Chronicle / Polaris) (FOTO:DUKAS/POLARIS)
    ©San Francisco Chronicle/Yalonda M. James

     

  • FDA approves deep-brain stimulation treatment for Parkinsons patients
    DUKAS_183263366_POL
    FDA approves deep-brain stimulation treatment for Parkinsons patients
    3/21/2025 - Palo Alto, California, USA: Parkinson’s patient John L. Lipp, CEO, Friends of the Alameda Animal Shelter (FAAS), second from left, listens to neurologist Gaurav Chattree, not pictured, Stanford University, during treatment at the Stanford Neuroscience Health Center in Palo Alto, Calif. on Friday, March 21, 2025. The FDA has recently approved a personalized treatment for Parkinson's, adaptive deep-brain stimulation. For the first time in the U.S., Stanford experts are using it for patients. (Yalonda M. James / San Francisco Chronicle / Polaris) (FOTO:DUKAS/POLARIS)
    ©San Francisco Chronicle/Yalonda M. James

     

  • FDA approves deep-brain stimulation treatment for Parkinsons patients
    DUKAS_183263364_POL
    FDA approves deep-brain stimulation treatment for Parkinsons patients
    3/21/2025 - Palo Alto, California, USA: Parkinson’s patient John L. Lipp, CEO, Friends of the Alameda Animal Shelter (FAAS), attends his treatment with neurologist Gaurav Chattree, Stanford University (not pictured), (not pictured) at the Stanford Neuroscience Health Center in Palo Alto, Calif. on Friday, March 21, 2025. The FDA has recently approved a personalized treatment for Parkinson's, adaptive deep-brain stimulation. For the first time in the U.S., Stanford experts are using it for patients. (Yalonda M. James / San Francisco Chronicle / Polaris) (FOTO:DUKAS/POLARIS)
    ©San Francisco Chronicle/Yalonda M. James

     

  • FDA approves deep-brain stimulation treatment for Parkinsons patients
    DUKAS_183263361_POL
    FDA approves deep-brain stimulation treatment for Parkinsons patients
    3/21/2025 - Palo Alto, California, USA: (Left to right): Amaza Reitmeier, VP and general manager of Neuromodulation Portfolio, Ken Washington, chief technology officer for Medtronic, Rob Raike, director of research and technology for Medtronic Neuromodulation, Angie Mason, district manager, Medtronic, and Meredith Vornholt, senior director of marketing at Brain Modulation, watch live results of Parkinson’s patient John L. Lipp’s treatment with neurologist Gaurav Chattree, Stanford University (both not pictured), at the Stanford Neuroscience Health Center in Palo Alto, Calif. on Friday, March 21, 2025. The FDA has recently approved a personalized treatment for Parkinson's, adaptive deep-brain stimulation. For the first time in the U.S., Stanford experts are using it for patients. (Yalonda M. James / San Francisco Chronicle / Polaris) (FOTO:DUKAS/POLARIS)
    ©San Francisco Chronicle/Yalonda M. James

     

  • FDA approves deep-brain stimulation treatment for Parkinsons patients
    DUKAS_183263358_POL
    FDA approves deep-brain stimulation treatment for Parkinsons patients
    3/21/2025 - Palo Alto, California, USA: Neurologist Dr. Helen Bronte-Stewart speaks with medical professionals during a treatment with Parkinson’s patient Keith Krehbiel at the Stanford Neuroscience Health Center in Palo Alto, Calif. on Friday, March 21, 2025. The FDA has recently approved a personalized treatment for Parkinson's, adaptive deep-brain stimulation. For the first time in the U.S., Stanford experts are using it for patients. Krehbiel, 70, a recently retired political science and ethics professor at Stanford University, was diagnosed with Parkinson’s in 1997. (Yalonda M. James / San Francisco Chronicle / Polaris) (FOTO:DUKAS/POLARIS)
    ©San Francisco Chronicle/Yalonda M. James

     

  • FDA approves deep-brain stimulation treatment for Parkinsons patients
    DUKAS_183263355_POL
    FDA approves deep-brain stimulation treatment for Parkinsons patients
    3/21/2025 - Palo Alto, California, USA: (Left to right): Pearl Yamaguchi, senior field clinical research manager for Medtronic, Parkinson’s patient Keith Krehbiel, neurologist Dr. Helen Bronte-Stewart, and Donna Gow, senior deep-brain stimulation (DBS) therapy specialist, San Francisco Bay Area, Medtronic, work during a treatment with Krehbiel at the Stanford Neuroscience Health Center in Palo Alto, Calif. on Friday, March 21, 2025. The FDA has recently approved a personalized treatment for Parkinson's, adaptive deep-brain stimulation. For the first time in the U.S., Stanford experts are using it for patients. Krehbiel, 70, a recently retired political science and ethics professor at Stanford University, was diagnosed with Parkinson’s in 1997. (Yalonda M. James / San Francisco Chronicle / Polaris) (FOTO:DUKAS/POLARIS)
    ©San Francisco Chronicle/Yalonda M. James

     

  • PEOPLE - Ein Strohdach für die Beckham-Luxus-Scheune in Chipping Norton
    DUK10075524_017
    PEOPLE - Ein Strohdach für die Beckham-Luxus-Scheune in Chipping Norton
    Mandatory Credit: Photo by Joan Wakeham/REX/Shutterstock (9138431l)
    Master Thatchers "Parkinsons" at work on the Beckham's barn near Chipping Norton
    Master Thatchers at work on the Beckham's barn near Chipping Norton, UK - 13 Oct 2017
    (c) Dukas

     

  • PEOPLE - Ein Strohdach für die Beckham-Luxus-Scheune in Chipping Norton
    DUK10075524_016
    PEOPLE - Ein Strohdach für die Beckham-Luxus-Scheune in Chipping Norton
    Mandatory Credit: Photo by Joan Wakeham/REX/Shutterstock (9138431j)
    Master Thatchers "Parkinsons" at work on the Beckham's barn near Chipping Norton
    Master Thatchers at work on the Beckham's barn near Chipping Norton, UK - 13 Oct 2017
    (c) Dukas

     

  • PEOPLE - Ein Strohdach für die Beckham-Luxus-Scheune in Chipping Norton
    DUK10075524_015
    PEOPLE - Ein Strohdach für die Beckham-Luxus-Scheune in Chipping Norton
    Mandatory Credit: Photo by Joan Wakeham/REX/Shutterstock (9138431k)
    Master Thatchers "Parkinsons" at work on the Beckham's barn near Chipping Norton
    Master Thatchers at work on the Beckham's barn near Chipping Norton, UK - 13 Oct 2017
    (c) Dukas

     

  • PEOPLE - Ein Strohdach für die Beckham-Luxus-Scheune in Chipping Norton
    DUK10075524_014
    PEOPLE - Ein Strohdach für die Beckham-Luxus-Scheune in Chipping Norton
    Mandatory Credit: Photo by Joan Wakeham/REX/Shutterstock (9138431a)
    Master Thatchers "Parkinsons" at work on the Beckham's barn near Chipping Norton
    Master Thatchers at work on the Beckham's barn near Chipping Norton, UK - 13 Oct 2017
    (c) Dukas

     

  • PEOPLE - Ein Strohdach für die Beckham-Luxus-Scheune in Chipping Norton
    DUK10075524_009
    PEOPLE - Ein Strohdach für die Beckham-Luxus-Scheune in Chipping Norton
    Mandatory Credit: Photo by Joan Wakeham/REX/Shutterstock (9138431b)
    Master Thatchers "Parkinsons" at work on the Beckham's barn near Chipping Norton
    Master Thatchers at work on the Beckham's barn near Chipping Norton, UK - 13 Oct 2017
    (c) Dukas

     

  • PEOPLE - Ein Strohdach für die Beckham-Luxus-Scheune in Chipping Norton
    DUK10075524_006
    PEOPLE - Ein Strohdach für die Beckham-Luxus-Scheune in Chipping Norton
    Mandatory Credit: Photo by Joan Wakeham/REX/Shutterstock (9138431i)
    Master Thatchers "Parkinsons" at work on the Beckham's barn near Chipping Norton
    Master Thatchers at work on the Beckham's barn near Chipping Norton, UK - 13 Oct 2017
    (c) Dukas

     

  • PEOPLE - Ein Strohdach für die Beckham-Luxus-Scheune in Chipping Norton
    DUK10075524_005
    PEOPLE - Ein Strohdach für die Beckham-Luxus-Scheune in Chipping Norton
    Mandatory Credit: Photo by Joan Wakeham/REX/Shutterstock (9138431q)
    Master Thatchers "Parkinsons" at work on the Beckham's barn near Chipping Norton
    Master Thatchers at work on the Beckham's barn near Chipping Norton, UK - 13 Oct 2017
    (c) Dukas

     

  • PEOPLE - Ein Strohdach für die Beckham-Luxus-Scheune in Chipping Norton
    DUK10075524_004
    PEOPLE - Ein Strohdach für die Beckham-Luxus-Scheune in Chipping Norton
    Mandatory Credit: Photo by Joan Wakeham/REX/Shutterstock (9138431p)
    Master Thatchers "Parkinsons" at work on the Beckham's barn near Chipping Norton
    Master Thatchers at work on the Beckham's barn near Chipping Norton, UK - 13 Oct 2017
    (c) Dukas

     

  • PEOPLE - Ein Strohdach für die Beckham-Luxus-Scheune in Chipping Norton
    DUK10075524_003
    PEOPLE - Ein Strohdach für die Beckham-Luxus-Scheune in Chipping Norton
    Mandatory Credit: Photo by Joan Wakeham/REX/Shutterstock (9138431o)
    Master Thatchers "Parkinsons" at work on the Beckham's barn near Chipping Norton
    Master Thatchers at work on the Beckham's barn near Chipping Norton, UK - 13 Oct 2017
    (c) Dukas

     

  • PEOPLE - Ein Strohdach für die Beckham-Luxus-Scheune in Chipping Norton
    DUK10075524_002
    PEOPLE - Ein Strohdach für die Beckham-Luxus-Scheune in Chipping Norton
    Mandatory Credit: Photo by Joan Wakeham/REX/Shutterstock (9138431m)
    Master Thatchers "Parkinsons" at work on the Beckham's barn near Chipping Norton
    Master Thatchers at work on the Beckham's barn near Chipping Norton, UK - 13 Oct 2017
    (c) Dukas

     

  • PEOPLE - Ein Strohdach für die Beckham-Luxus-Scheune in Chipping Norton
    DUK10075524_001
    PEOPLE - Ein Strohdach für die Beckham-Luxus-Scheune in Chipping Norton
    Mandatory Credit: Photo by Joan Wakeham/REX/Shutterstock (9138431n)
    Master Thatchers "Parkinsons" at work on the Beckham's barn near Chipping Norton
    Master Thatchers at work on the Beckham's barn near Chipping Norton, UK - 13 Oct 2017
    (c) Dukas

     

  • PEOPLE - Vermisste Schauspielerin Naya Rivera (Archiv)
    DUK10133776_002
    PEOPLE - Vermisste Schauspielerin Naya Rivera (Archiv)
    Mandatory Credit: Photo by Brian To/Variety/Shutterstock (5799943i)
    Ryan Dorsey and Naya Rivera
    'Raising The Bar to End Parkinsons' Fundraiser, Arrivals, Los Angeles, USA - 27 Jul 2016
    (c) Dukas

     

  • PEOPLE - Vermisste Schauspielerin Naya Rivera (Archiv)
    DUK10133776_001
    PEOPLE - Vermisste Schauspielerin Naya Rivera (Archiv)
    Mandatory Credit: Photo by Brian To/Variety/Shutterstock (5799943g)
    Ryan Dorsey and Naya Rivera
    'Raising The Bar to End Parkinsons' Fundraiser, Arrivals, Los Angeles, USA - 27 Jul 2016
    (c) Dukas

     

  • Next page